Search our website

Posters

VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
June 6th, 2022
VBI Vaccines to Present at Upcoming Scientific Conferences
June 17th, 2021
VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM
June 8th, 2021
VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021
May 3rd, 2021
VBI Vaccines Announces Positive Interim Phase 2a Data from VBI-1901 in Recurrent GBM
November 19th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at The Liver Meeting® 2020
November 13th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at ID Week 2020™
October 26th, 2020
VBI Vaccines Announces Biomarker Data from VBI-1901 Phase 1/2a Study in Recurrent GBM Presented at ESMO Virtual Congress 2020
September 17th, 2020
VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020
August 31st, 2020
VBI Vaccines Announces Data from VBI-1901 Presented at AACR 2020: Partial Response Observed, Promising Biomarker Strategy Identified
June 22nd, 2020
VBI Vaccines Presents Early GBM Tumor Response and Immunologic Data from Part B of Ongoing Phase 1/2a Study of VBI-1901 at the 2019 SNO Annual Meeting
November 22nd, 2019
VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019
October 22nd, 2019
VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019
June 4th, 2019
VBI Vaccines Announces Late-Breaking Poster Presentation at EASL 2019
April 9th, 2019
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
October 24th, 2018

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up NowArrow
Go top